Current Class Of Risk Evaluation & Mitigation Strategies
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Here is a general outline of the REMS FDA has mandated so far, as well as a listing of drugs where it has been announced that REMS are being developed or drugs with safety issues that could invoke a REMS.
You may also be interested in...
Reimbursement Questions Jeopardize Hillrom/Bardy Merger
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics due to doubts about Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.
Boston Scientific Pays More Than $1Bn For Lumenis’ Surgical Laser Business
Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.
Finance Watch: Eleven Companies Reveal $1.45bn In $100m-Plus VC Deals
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: